WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319937

CAS#: 282526-98-1

Description: Cetilistat, also known as ATL-962, is a drug designed to treat obesity. It acts in the same way as the older drug orlistat (Xenical) by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.

Price and Availability

Size Price Shipping out time Quantity
500mg USD 90 2 Weeks
1g USD 150 2 Weeks
2g USD 250 2 Weeks
5g USD 450 2 Weeks
10g USD 650 2 Weeks
20g USD 950 2 Weeks
50g USD 1450 2 Weeks
100g USD 1850 2 Weeks
200g USD 2450 2 Weeks
500g USD 2950 2 Weeks
1kg USD 3950 2 Weeks
2kg USD 4950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-20. Prices are subject to change without notice.

Cetilistat, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 319937
Name: Cetilistat
CAS#: 282526-98-1
Chemical Formula: C25H39NO3
Exact Mass: 401.293
Molecular Weight: 401.591
Elemental Analysis: C, 74.77; H, 9.79; N, 3.49; O, 11.95

Synonym: ATL-962; ATL962; ATL 962; Cetilistat

IUPAC/Chemical Name: 2-(hexadecyloxy)-6-methyl-4H-benzo[d][1,3]oxazin-4-one


InChi Code: InChI=1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

In human trials, cetilistat was shown to produce similar weight loss to orlistat, but also produced similar side effects such as oily, loose stools, fecal incontinence, frequent bowel movements, and flatulence. It is likely that the same precautions would apply in that absorption of fat-soluble vitamins and other fat-soluble nutrients may be inhibited, requiring vitamin supplements to be used to avoid deficiencies.

Cetilistat has completed Phase 1 and 2 trials in the West and is currently in Phase 3 trials in Japan where it is partnered with Takeda. Norgina BV has now acquired the full global rights to cetilistat from Alizyme after the latter went into administration.


1: Zimmerman MP, Mehr SR. Nonincretin drugs in later-stage development. Am J Manag Care. 2014 Jan;20(1 Spec No.):E2. PubMed PMID: 25618226.

2: Johansson M, Fransson D, Rundlöf T, Huynh NH, Arvidsson T. A general analytical platform and strategy in search for illegal drugs. J Pharm Biomed Anal. 2014 Nov;100:215-29. doi: 10.1016/j.jpba.2014.07.026. Epub 2014 Aug 4. PubMed PMID: 25171485.

3: Cheung BM, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther Adv Drug Saf. 2013 Aug;4(4):171-81. doi: 10.1177/2042098613489721. PubMed PMID: 25114779; PubMed Central PMCID: PMC4125319.

4: Hainer V. Overview of new antiobesity drugs. Expert Opin Pharmacother. 2014 Oct;15(14):1975-8. doi: 10.1517/14656566.2014.946904. Epub 2014 Aug 6. Review. PubMed PMID: 25100293.

5: Hainer V, Aldhoon-Hainerová I. Tolerability and safety of the new anti-obesity medications. Drug Saf. 2014 Sep;37(9):693-702. doi: 10.1007/s40264-014-0206-3. Review. PubMed PMID: 25096956.

6: Durgampudi C, Noel P, Patel K, Cline R, Trivedi RN, DeLany JP, Yadav D, Papachristou GI, Lee K, Acharya C, Jaligama D, Navina S, Murad F, Singh VP. Acute lipotoxicity regulates severity of biliary acute pancreatitis without affecting its initiation. Am J Pathol. 2014 Jun;184(6):1773-84. doi: 10.1016/j.ajpath.2014.02.015. PubMed PMID: 24854864; PubMed Central PMCID: PMC4044711.

7: Ueno H, Nakazato M. [Cutting-edge of medicine; the prospects of novel anti-obesity drugs]. Nihon Naika Gakkai Zasshi. 2014 Mar 10;103(3):753-9. Review. Japanese. PubMed PMID: 24796150.

8: Gras J. Cetilistat for the treatment of obesity. Drugs Today (Barc). 2013 Dec;49(12):755-9. doi: 10.1358/dot.2013.49.12.2099318. PubMed PMID: 24524093.

9: George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):65-76. doi: 10.1177/1074248413501017. Epub 2013 Sep 24. Review. PubMed PMID: 24064009.

10: Carter R, Mouralidarane A, Ray S, Soeda J, Oben J. Recent advancements in drug treatment of obesity. Clin Med (Lond). 2012 Oct;12(5):456-60. Review. PubMed PMID: 23101148.

11: Simonyi G, Pados G, Medvegy M, Bedros JR. [The pharmacological treatment of obesity: past, present and future]. Orv Hetil. 2012 Mar 11;153(10):363-73. doi: 10.1556/OH.2012.29317. Review. Hungarian. PubMed PMID: 22370224.

12: Faria AM, Mancini MC, Melo ME, Cercato C, Halpern A. [Recent progress and novel perspectives on obesity pharmacotherapy]. Arq Bras Endocrinol Metabol. 2010 Aug;54(6):516-29. Review. Portuguese. PubMed PMID: 20857056.

13: Hainer V. [Drug treatment of obesity--current situation and perspectives]. Cas Lek Cesk. 2010;149(11):513-9. Review. Czech. PubMed PMID: 21391349.

14: Kopelman P, Groot Gde H, Rissanen A, Rossner S, Toubro S, Palmer R, Hallam R, Bryson A, Hickling RI. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010 Jan;18(1):108-15. doi: 10.1038/oby.2009.155. Epub 2009 May 21. PubMed PMID: 19461584.

15: Bryson A, de la Motte S, Dunk C. Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Br J Clin Pharmacol. 2009 Mar;67(3):309-15. doi: 10.1111/j.1365-2125.2008.03311.x. Epub 2008 Sep 19. PubMed PMID: 19220279; PubMed Central PMCID: PMC2675041.

16: Yamada Y, Kato T, Ogino H, Ashina S, Kato K. Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats. Horm Metab Res. 2008 Aug;40(8):539-43. doi: 10.1055/s-2008-1076699. Epub 2008 May 21. PubMed PMID: 18500680.

17: Padwal R. Cetilistat, a new lipase inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2008 Apr;9(4):414-21. Review. PubMed PMID: 18393108.

18: Zieba R. [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. Postepy Hig Med Dosw (Online). 2007 Oct 19;61:612-26. Review. Polish. PubMed PMID: 17971763.

19: Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, Valensi P. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007 Mar;31(3):494-9. Epub 2006 Sep 5. PubMed PMID: 16953261.

20: Halford JC. Obesity drugs in clinical development. Curr Opin Investig Drugs. 2006 Apr;7(4):312-8. Review. PubMed PMID: 16625817.